Mirum Pharmaceuticals Inc (NASDAQ: MIRM) flaunted slowness of -4.81% at $40.60, before settling in for the price of $42.65 at the close. Taking a more long-term approach, MIRM posted a 52-week range of $23.14-$48.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 88.90%. Meanwhile, its Annual Earning per share during the time was -39.57%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 58.14%. This publicly-traded company’s shares outstanding now amounts to $47.97 million, simultaneously with a float of $38.27 million. The organization now has a market capitalization sitting at $1.95 billion. At the time of writing, stock’s 50-day Moving Average stood at $41.92, while the 200-day Moving Average is $34.97.
Mirum Pharmaceuticals Inc (MIRM) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Mirum Pharmaceuticals Inc industry. Mirum Pharmaceuticals Inc’s current insider ownership accounts for 20.29%, in contrast to 94.36% institutional ownership. According to the most recent insider trade that took place on Nov 14 ’24, this organization’s SVP, GLOBAL CONTROLLER sold 2,500 shares at the rate of 47.10, making the entire transaction reach 117,752 in total value, affecting insider ownership by 2,426. Preceding that transaction, on Sep 18 ’24, Company’s Director bought 115 for 37.40, making the whole transaction’s value amount to 4,301. This particular insider is now the holder of 162,308 in total.
Mirum Pharmaceuticals Inc (MIRM) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
Mirum Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 58.14% and is forecasted to reach -0.73 in the upcoming year.
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Trading Performance Indicators
Let’s observe the current performance indicators for Mirum Pharmaceuticals Inc (MIRM). It’s Quick Ratio in the last reported quarter now stands at 3.15. The Stock has managed to achieve an average true range (ATR) of 1.94. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.35.
In the same vein, MIRM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.07, a figure that is expected to reach -0.30 in the next quarter, and analysts are predicting that it will be -0.73 at the market close of one year from today.
Technical Analysis of Mirum Pharmaceuticals Inc (MIRM)
Now, what If we examine the latest scores posted by [Mirum Pharmaceuticals Inc, MIRM]. During the last 5-days, its volume was lower the volume of 0.54 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 18.86% While, its Average True Range was 1.93.
Raw Stochastic average of Mirum Pharmaceuticals Inc (MIRM) in the period of the previous 100 days is set at 34.67%, which indicates a major rise in contrast to 8.09% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 27.26% that was lower than 42.90% volatility it exhibited in the past 100-days period.
